

DNAJC12 in monoamine metabolism, neurodevelopment and neurodegeneration

Isaac Bul Deng¹, Jordan Follett¹, Mengfei Bu¹ and Matthew J. Farrer^{1*}

¹Department of Neurology, and Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, Florida, USA.

***Corresponding author:** Matthew J. Farrer (email: m.farrer@ufl.edu)

Word count: 4,726 including figure legends and tables.

Figures: 3

Supplementary figures: 1

Supplementary tables: 1

Abstract

Recent studies show that mutations in *DNAJC12*, a co-chaperone for monoamine synthesis may cause mild hyperphenylalaninemia with infantile dystonia, young-onset parkinsonism, developmental delay and cognitive deficits. To this end, *DNAJC12* gene has been included in newborn screening, most revealingly in Spain, and those results are a testament to the importance of early diagnosis and treatment in combating human diseases. However, practitioners may be unaware of these advances and it is probable that many patients, especially adults, have yet to receive molecular testing for *DNAJC12*. Therefore, this review summarizes genotype-phenotype relationships and treatment paradigms for patients with *DNAJC12* mutations. It provides an overview of the structure of *DNAJC12* protein, known mutations, domains and binding partners, and elaborates on its role in monoamine synthesis, disease etiology and pathogenesis.

Introduction

Molecular chaperones are molecularly and functionally diverse families of proteins essential for protein folding, trafficking and degradation.^{1,2} Often termed heat shock proteins (HSPs), these include HSP90, HSP70, HSP60, HSP40 and the small HSPs. HSP40 proteins, also known as DNAJ proteins, are further divided into three classes: DNAJAs, DNAJBs and DNAJCs, based on the composition of their domains.^{1,2} DNAJ-containing proteins bind to specific client proteins and HSP-70, synergistically positioning them in proximity to the J-domain to stimulate the ATPase activity of HSP-70, in turn liberating both ADP and folded substrate from this reaction.² HSP-70 protects client proteins' hydrophobic ends, facilitating folding and preventing protein aggregation.^{2,3} In addition, HSP-70 chaperones target proteins implicated in neurodegeneration including alpha-synuclein and tau for degradation by chaperone-mediated autophagy.⁴⁻⁶ Thus, DNAJ-domain containing proteins are necessary to maintain the cellular proteome.

Recent studies show that biallelic recessively-inherited mutations in *DNAJC12*, a member of the DNAJC family of co-chaperones, result in a multitude of neurological symptoms, including developmental delay, intellectual disability, neuropsychiatric disorders, infantile dystonia or young-onset parkinsonism. Mutations in *DNAJC12* also account for a small proportion of hyperphenylalaninemia (HPA) cases that are not attributed to mutations in phenylalanine hydroxylase (PAH) or synthesis of its co-factor tetrahydrobiopterin (BH₄).⁷⁻⁹ The role of DNAJC12 protein is not fully understood, but it appears to function as a co-chaperone for aromatic amino acid hydroxylases (AAAHs) including PAH, tyrosine hydroxylase (TH) and tryptophan hydroxylase 1 and 2 (TPH1 and TPH2), which are essential for the synthesis of dopamine and serotonin. These neurotransmitters are markedly reduced in patients with *DNAJC12* mutations.^{7,8} *DNAJC12* mutations were first discovered in children with HPA, neurodevelopmental delay and dystonia⁷, and in patients and families with young-onset parkinsonism⁸, and were quickly appreciated to be important in the differential diagnosis of HPA.¹⁰ *DNAJC12* is the fifth DNAJC family member to be implicated in parkinsonism, with others

including DNAJC5 (cysteine string protein- α), DNAJC6 (auxillin), DNAJC13 (receptor-mediated endocytosis-8) and DNAJC26 (cyclin G associated kinase (GAK)).^{11–14} Hence, understanding the role of DNAJC12 in monoamine synthesis may reveal novel strategies to reestablish monoamine levels in neurological disorders. A summary of the genotype–phenotype relationship is warranted in patients with DNAJC12 mutations, along with a literature review on DNAJC12 protein function, binding partners, and its role in monoamine synthesis.

Monoamine Biosynthesis

Monoamines (include the catecholamines: dopamine, noradrenaline and adrenaline, and serotonin) fulfill multifunctional roles as neurotransmitters, trophic factors, hormones, and modulators of many physiological processes (Fig 1).^{15–18} The synthesis of catecholamines starts with the amino acid tyrosine which can be obtained from diet or produced in the liver from hydroxylation of phenylalanine by PAH. The catecholaminergic neurons and adrenal glands synthesize catecholamines according to cell-specific pathways, but with overlapping biochemistry using the same metabolic steps, enzymes, substrates and co-factors. In dopaminergic neurons, tyrosine is hydroxylated by TH to form dihydroxyphenylalanine (L-DOPA).^{17,19} Aromatic amino acid decarboxylase (AADC) decarboxylates L-DOPA to form dihydroxyphenethylamine (dopamine), which is the principal neurotransmitter of dopaminergic neurons. Adrenergic neurons that express the enzyme dopamine β -hydrolase (DH) convert dopamine into noradrenaline, whereas chromaffin cells in the adrenal medulla that express phenylethanolamine-N-methyl transferase (PNMT) convert noradrenaline to adrenaline.^{17,19} In contrast, serotonin synthesis involves the hydroxylation of an essential amino acid tryptophan to produce 5-hydroxytryptophan (5-HTP). This reaction is facilitated by TPH1 in the enterochromaffin cells (EC) of the gastrointestinal (GI) mucosa, pancreatic islets, mammary glands, and adipose tissue, and by TPH2 predominantly in the central nervous system (CNS). Subsequently, 5-HTP is decarboxylated by AADC to form serotonin. Notably, 90-95% of the total body serotonin is synthesized by EC.¹⁶ The synthesis of monoamines requires BH₄ as a co-factor for PAH, TH, TPH1 and TPH2. BH₄ is synthesized from

guanosine triphosphate (GTP) with GTP cyclohydrolase 1 (GTPCH1, encoded by *GCH1*) as a rate-limiting enzyme, and deficiencies in its synthesis and recycling compromise the production of monoamines. In addition, DNAJC12 supports the synthesis of monoamines as a co-chaperone for PAH, TH, TPH1 and TPH2.^{7,8}

Disorders of monoamines

Disorders of monoamines due to defects in BH₄ synthesis and recycling, enzymes involved in monoamine biosynthesis and catabolism, and monoamine transporter defects, lead to rare neurological disorders which manifest in childhood.²⁰ Disorders of BH₄ synthesis and recycling include autosomal dominant GTPCH1 deficiency caused by rare mutations in the *GCH1* gene, autosomal recessive GTPCH1 deficiency, or may result from sepiapterin reductase (SR) deficiency, 6-pyruvoyltetrahydropterin synthase (PTPS) deficiency, dihydropteridine reductase (DHPR) deficiency or pterin-4a-carbinolamine dehydratase (PCD) deficiency. BH₄ disorders are marked by a reduction in dopamine and serotonin, and consequently by a multitude of neurological complications, mostly co-occurring in the same patients, which include developmental delay, axial hypotonia, dystonia, parkinsonism, neuropsychiatric disturbances, cognitive disabilities and autonomic dysfunction.^{21–23} Of the BH₄ disorders, PCD deficiency is the only one marked by the absence of severe neurological symptoms. Patients with BH₄ disorders benefit immensely from treatment with neurotransmitter precursors (L-DOPA and 5-HTP) and/or BH₄ therapy. However, the latter must be avoided in patients with defective BH₄ recycling due to the potential accumulation of harmful BH₄ metabolites.^{20,24} BH₄ is also a co-factor for nitric oxide synthases and has been implicated in neuropathic and inflammatory pain. Pain is commonly reported in many neurodegenerative diseases and its management is based on clinical experience as there are limited treatment guidelines.²⁵ *In-vivo*, axonal and peripheral injury elevates *GCH1* protein and activity, causing increased levels of BH₄ and enhanced pain hypersensitivity. Such phenotypes can be ameliorated via knockout of *GCH1* or pharmacological inhibition of SR, which reduces the levels of BH₄.^{26,27} In addition, it has been reported that certain

polymorphisms in human *GCH1* protect against pain by reducing the levels of BH₄, yet in a manner that maintains sufficient baseline activity of the enzyme such that the monoamine-associated neurological disorders are circumvented.^{26–28} Thus, further research to understand the BH₄ pathway could unveil novel strategies to alleviate pain. Deficiency in the primary enzymes involved in monoamine biosynthesis such as TH and AADC, result in monoamine deficiency and neurological features that resemble BH₄ disorders.^{29,30} These disorders, along with monoamine catabolism and transporter disorders, are reviewed in more detail by Brennenstuhl and colleagues.²⁰ Genetic variants in the newly described molecular co-chaperone, DNAJC12, cause neurological features that resemble BH₄ disorders and broaden the spectrum of monoamine disorders²⁰, as elaborated below.

DNAJC12 structure and binding partners

The *DNAJC12* gene is located on chromosome 10q21.3. It has five exons and can be alternatively spliced to generate two transcripts.³¹ The longer *DNAJC12* transcript encodes the full-length protein of 198 amino acids, while a shorter transcript encodes a protein of 107 amino acids.³¹ DNAJC12 protein is expressed predominately in the cytoplasm; it contains a J-domain and a highly conserved C-terminus without other known functional domains (Fig 2A).³¹ It is prominently expressed in the brain, adrenal glands and liver (https://www.proteinatlas.org/ENSG00000108176-DNAJC12/tissue#rna_expression). While the role of DNAJC12 has yet to be fully elucidated, it is widely regarded as a co-chaperone for AAHs such as PAH, TH, TPH1 and TPH2.^{2,7} DNAJC12 interacts with PAH *in-vitro* and *in-vivo*, and as a corollary, PAH protein and activity are reduced in the fibroblasts of patients with *DNAJC12* mutations^{7,32} while dopamine and serotonin are reduced in their cerebrospinal fluid, consistent with the role of DNAJC12 as a co-chaperone for TH and TPH2.^{7,33} Notably, DNAJC12 is a binding partner of BiP/GRP78, a critical ER HSP-70 chaperone that is upregulated with ER stress.³¹ The ER transcription factor AlbZIP also increases DNAJC12 protein expression during ER stress, exerting its effects on the *DNAJC12* promoter.³¹ As HSC-70 interacts with TH, AADC and the vesicular monoamine transporter (VMAT2), DNAJC12 appears to be indirectly involved in dopamine synthesis and packaging^{34–36}, however further work is necessary to validate this connection.

Genotype and phenotype relationships in patients with *DNAJC12* mutations

Literature search and selection criteria

A literature search was performed using PubMed and Google Scholar with the following keywords: hyperphenylalaninemia or phenylketonuria, *DNAJC12* or heat shock protein 40 (HSP40). This search yielded 216 articles which included a total of 639 patients with HPA (including patients with non-BH₄ or BH₄ HPA). After four patients were excluded with heterozygous mutations in *PAH*, 52 patients (8.1%) with HPA were found to have biallelic or heterozygous mutations in *DNAJC12*. Clinical data was ultimately extracted from 15 articles published between 2017 and 2023. *DNAJC12* variants are classified as pathogenic, likely pathogenic and likely benign according to the guidelines of the American College of Medical Genetics and Genomics and Association of Molecular Pathology³⁷, and were also identified within Clinvar, GnomAD and Uniprot databases (Fig 2B).

Overview of patients with *DNAJC12* mutations

Biallelic pathogenic variants in *DNAJC12* were first identified via whole exome sequencing in six affected children from four unrelated consanguineous families from Morocco, Turkey, and Saudi Arabia.⁷ Five of the six patients were investigated because of a neonatal/pediatric movement disorder resembling a BH₄ deficiency syndrome with HPA, infantile dystonia and progressive neurodevelopmental delay. High-throughput sequencing excluded mutations in *PAH*, whereas deficiencies in BH₄ were ruled out by assessing urinary pterin metabolites and DHPR activity in dried blood spots. One of the six individuals was immediately treated with a combination of neurotransmitter precursors (L-DOPA and 5-HTP), BH₄ and folinic acid due to prior history of HPA within their family, and they were spared from neurological deficits.⁷ Such findings suggest that much of the neurodevelopmental phenotype attributed to *DNAJC12* mutations can be prophylactically managed via early diagnosis and timely treatment. A second independent study in Canadian and Italian families used comparative whole exome sequencing to successfully identify biallelic *DNAJC12* mutations as a cause

of young-onset parkinsonism.⁸ It appeared that HPA was only apparent in one of three affected individuals. However, prominent features in all patients were mild intellectual disability and L-DOPA-responsive nonprogressive parkinsonism with dyskinesia, which were not associated with dopaminergic deficits by presynaptic nigrostriatal imaging.⁸ Thus, these patients might constitute cases of “scans without evidence of dopaminergic deficits” an enigmatic clinical dilemma that is also evident in patients with Parkinson’s disease (PD) and levodopa-responsive dystonia.^{38–40} With the recognition that recessively inherited *DNAJC12* loss-of-function mutations may cause HPA, this gene has recently been included in newborn genetic testing.^{41–44} Recognizing this bias and based on patients identified with *DNAJC12* mutations between 2017–2023 (Fig 3A to B), the most predominant features in the first decade include developmental delay, attention deficit hyperactivity disorder (ADHD), speech delay, intellectual disability, autism, axial hypotonia and dystonia. In the second decade, the phenotype is marked by prominent parkinsonism, dystonia, axial hypotonia, with/without intellectual disability, and to a lesser extent, psychiatric features, ADHD or other cognitive deficits. Clinical data from the third decade is scant, given a lack of genetic testing in this age group, but the symptomology includes young-onset parkinsonism, cognitive deficits and psychiatric features.

Genetics variants and clinical features of patients with *DNAJC12* mutations

A total of 52 patients was identified with biallelic or heterozygous *DNAJC12* mutations originating from 11 countries (missing data: 3 patients) located in Europe, Asia, the Middle East, and North Africa (Fig 3D). Seventy-five percent of patients (39 patients) were homozygous and 25% (13 patients) were compound heterozygotes. The types of *DNAJC12* mutations included nonsense (34.6%, 18 patients), splice site (26.9%, 14 patients), frameshift (11.5%, 6 patients), missense variants (1.9%, 1 patient) and others, which refer to compound heterozygous variants with two different types of mutations (25%, 13 patients) (Fig S1). Neurological features vary markedly among patients with *DNAJC12* mutations, even within siblings with the same genotype, and the age of onset ranged from 22 months to 59 years. Detailed clinical data is provided in Table S1. In brief, patients with *DNAJC12* mutations had movement

disorders exemplified by axial hypotonia (15.4%, 8 patients), dystonia (15.4%, 8 patients) and parkinsonism (13.5%, 7 patients), which co-exist in some patients.^{7,8,44–46} Recessively inherited, biallelic *DNAJC12* variants are a rare cause of young-onset L-DOPA-responsive parkinsonism;⁸ although heterozygous variants neither appear to be a risk factor nor a genome-wide associated locus for idiopathic PD.^{47–49} Other neurological features include global developmental delay (19.2%, 10 patients), intellectual disability (19.2%, 10 patients), cognitive deficits (15.4%, 8 patients), speech delays (15.4%, 8 patients), ADHD (13.5%, 7 patients), autism (11.5%, 6 patients) and other psychiatric features (7.7%, 4 patients).^{42,43,50} Many of these features co-occur in the same patients and are developmental or associated with age. Of note, 40.4% (21 patients) of patients with *DNAJC12* mutations (ranging from 6 – 40 years old) carried a homozygous (13 patients) or heterozygous (8 patients) p. Trp175* variant, which was only reported in patients with a Spanish origin.^{51,52} Increased cases of *DNAJC12*-induced HPA recognized in the Spanish population reflect this country's comprehensive implementation of *DNAJC12* sequencing in newborn genetic screening.⁵¹ Of the patients with homozygous p. Trp175* variants in *DNAJC12*, 2 had unknown neurological status, 10 were neurologically asymptomatic, and only 1 patient was reported with neurological features, which included ADHD, autism and intellectual disability. Conversely, patients with a heterozygous p. Trp175* variant included 2 that were asymptomatic, 3 symptomatic and 3 with an unknown neurological status. These findings suggest that specific genetic or environmental factors govern the penetrance of p. Trp175* in the Spanish population. Of note, p. Trp175* is a nonsense variant that results in a premature stop codon in the last exon of the *DNAJC12* gene, which is predicted to result in a protein that is 23 amino acids shorter at the C-terminus. Although it hasn't been examined in homozygous p. Trp175* patients, *DNAJC12* protein is markedly reduced in the fibroblasts of heterozygous patients compared to matched controls.⁵¹ Notably, 42.3% of individuals with *DNAJC12* mutations (22 patients) were reported to be neurologically asymptomatic. Some individuals described as asymptomatic refused to perform neuropsychometric tests, and in some, it was unclear whether more informative exams might have identified more subtle

neurological features. Therefore, some phenotypes may have been missed in seemingly asymptomatic individuals with *DNAJC12* mutations.

Diagnosis and treatment in patients with *DNAJC12* mutations

DNAJC12 mutations are mostly found when newborns with HPA undergo whole exome sequencing or when individual patients are investigated for developmental delay with motor complications.^{7,8,33} *DNAJC12* mutations elevate the levels of Phe in the blood and result in dopamine and serotonin deficiency. *DNAJC12* patients would continue to experience a progressive increase in Phe levels without intervention since they cannot correctly metabolize this amino acid, which has severe neurological consequences.⁹ As a result, the standard treatment in patients with *DNAJC12* mutations is a Phe-restricted diet to maintain low levels of Phe in children, adolescents and adults.⁹ The literature is variable regarding the blood Phe concentration required to start treatment. There is a consensus that patients with untreated blood Phe concentration of >600 µmol/L should commence treatment while patients with <360 remain untreated. Unfortunately, it is unclear whether patients with untreated blood Phe concentration >360 should be treated.^{53,54} Only one study reported that patients with untreated blood Phe concentration >360 have similar neuropsychological scores compared to control individuals, except in their executive function.⁵⁵ A Phe-restricted diet is often coupled with oral dopamine and serotonin precursors (L-DOPA and 5-HTP, respectively) to compensate for neurotransmitter deficiency and may include other supplements, including sapropterin dihydrochloride (a synthetic BH₄), folinic acid, selegiline, entacapone and pramipexole. Such treatment has ameliorated neurological features in 12 of 18 patients, with those in their first three months of life responding best with almost complete restoration of neurological function.^{7,33,42,50,56,57} Thirteen percent of the patients (7 patients) had BH₄ treatment with or without a Phe-restricted diet, and 4 responded positively, including improved cognition and motor function, and 3 were allowed to return to their unrestricted diet.^{7,33} The beneficial effects of BH₄ may be attributed to its role as a co-factor for AAHs, enhancing the stability of PAH, TH and TPH2.⁵⁸ Eight percent of the patients (4 patients) were treated with oral L-DOPA, possibly combined

with a Phe-restricted diet.⁸ Of these, 3 had L-DOPA-responsive parkinsonism but developed dyskinesia. Nevertheless, in 9.6 % (5 patients), the treatment status is unknown⁵², and 32.7% (17 patients) have yet to commence any treatment.^{51,59} While all untreated individuals had mild HPA, most were otherwise asymptomatic.

Proposed pathological mechanisms in DNAJC12 patients

The pathogenesis of neurological problems in patients with *DNAJC12* mutation is not fully understood. A Phe-restricted diet alleviates many neurological features, complementary to findings for phenylketonuria, a disorder of Phe metabolism caused by PAH deficiency, therefore suggesting that HPA is similarly toxic.^{33,50,51} Multiple mechanisms underlying those effects have been proposed, from deficits in lipid metabolism, cholesterol synthesis and oligodendrocyte myelination, to impaired glucose metabolism and large amino acid transport, to monoamine deficiency. Nevertheless, the relative contribution of *DNAJC12* loss-of-function to patients' phenotypes has yet to be elucidated.

White matter lesions

White matter disruption is strongly associated with HPA, and to our knowledge, has yet to be investigated in patients with *DNAJC12* mutations.³³ The precise mechanisms underlying white matter abnormalities are not well understood. Nonetheless, a leading hypothesis is that HPA impairs myelination in the brain.^{9,60,61} Congruent with this hypothesis, HPA changes the phenotype of oligodendrocytes from myelinating to non-myelinating in mice with biallelic *PAH* mutations.^{9,62} Such findings are consistent with *in-vitro* experiments showing that HPA reduces myelin basic protein in cerebellar organotypic slices.⁶³ However, other *in-vitro* studies claim oligodendrocytes are capable of synthesizing myelin sheath under HPA, suggesting other mechanisms are involved in demyelination.⁶⁴ A portion of the myelin lipid is made up of cholesterol, and an alteration in cholesterol synthesis could impair the formation of myelin sheath; hence, hypomyelination. In PAH-deficient mice, HPA inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), a rate-limiting enzyme in the

synthesis of cholesterol in the forebrain. There was also a reduction in HMGR activity and cholesterol levels in the forebrain of PKU mice.⁶⁵

Deficiency in monoamines

Deficiency in central dopamine and serotonin is a core feature of patients with *DNAJC12* mutations, and this is congruent with the role of *DNAJC12* as a co-chaperone for monoamines.^{7,8,33} HPA may also inhibit the influx of large neural amino acids (LNAAs) into the brain through Phe-mediated competition.^{9,66} These LNAAs include tyrosine and tryptophan which are essential for the synthesis of dopamine and serotonin, respectively. The synthesis of the latter monoamines could also be instigated by Phe-induced competitive inhibition of TH and TPH2 activities.⁶⁷ Catecholamines such as noradrenaline and adrenaline are downstream of dopamine in the catecholamine synthesis pathway, and may also be affected by *DNAJC12* deficiency. However, these neurotransmitters/hormones have yet to be examined in patients with *DNAJC12* mutations. Dopamine is essential for movement, attention, addiction, reward, cognition, arousal, wakefulness, memory formation and consolidation.^{17,68–70} These functions are under the control of three large dopaminergic neural circuits in the CNS; namely, the nigrostriatal pathway, the mesocortical pathway and the mesolimbic pathway.¹⁷ The nigrostriatal pathway consists of midbrain dopaminergic neurons in the *substantia nigra pars compacta* (SNpc), which send their axons to the caudate and putamen, to primarily control movement initiation. The mesocortical pathway consists of midbrain dopaminergic neurons in the adjacent ventral tegmental area (VTA), which project to the prefrontal cortex (PFC) that is pivotal for executive skills, attention, planning and decision-making. The mesolimbic pathway also originates in the VTA, whereby dopaminergic neurons send their projections to the hippocampus, amygdala and nucleus accumbens, with a role in processing and formation of emotion, learning, working memory and long-term memory. Hence, dysfunction in dopaminergic neural circuits may have multiple roles in the neurological problems experienced by *DNAJC12* patients, such as parkinsonism, dystonia, ADHD, intellectual disability and cognition. It is important to note that catecholamines have an essential role in the periphery which may

also be compromised by *DNAJC12* mutations. Secreted into the blood as hormones in the fight or flight response, the catecholamines increase pupil dilation, heart rate, blood sugar levels and blood flow to muscles. Also, they have direct effects on peripheral organs including the heart, blood vessels, kidney, liver, pancreas, stomach, brown adipose tissue and the immune system.^{15,18,71,72}

Serotonin in the CNS is severely reduced in patients with *DNAJC12* mutations, and this neurotransmitter is integral in neurite outgrowth, synaptogenesis and neurogenesis.⁷³ Serotonergic innervation originates predominately in the raphe nuclei in the brainstem, and is widely distributed throughout the CNS.⁷⁴ Impaired serotonin is well documented in neurodevelopmental disorders such as autism and in neuropsychiatric and mood disorders, including anxiety, apathy and depression, all of which are among the plethora of neurological features documented in patients with *DNAJC12* mutations.^{73–76} Serotonin is involved in GI motility and inflammation, and also functions in muscle constriction in the lung and uterus. It affects blood vessel constriction and dilation, platelet aggregation and nociceptive pain, all of which may be impacted by *DNAJC12* mutations^{77,78}. The diverse effects of serotonin in the periphery and brain, make it a potential regulator of the gut-brain axis. Considering the pleiotropic functions of monoamines, a conditional cre/loxP *Dnajc12* knockout model would be a singular, but comprehensive approach to study catecholamine communication between the periphery, basal ganglia and cortex.

Discussion

DNAJC12 mutations were discovered in 2017 as a new cause of HPA with neurodevelopmental and motor disorders.^{7,8} Newborn screening for *DNAJC12* mutations can now identify cases of mild HPA, unexplained by mutations in PAH and BH₄, and can ensure earlier treatment. Most disease-causing mutations appear to be recessively inherited and are a loss-of-function. However, variants such as p.Trp175* may retain partial function and have reduced penetrance. All patients with *DNAJC12* mutations, irrespective of their neurological symptoms, should start treatment to reduce Phe if diagnosed with HPA. However, maintaining an adequate protein diet is important in developing children

and is challenging.⁹ Pegvaliase, a bacterial-derived phenylalanine ammonia lyase (PAL), conjugated to polyethylene glycol (PEG) to reduce immunogenicity^{54,79}, was recently approved by Food and Drug Administration for the treatment of PKU, and it provides a new approach for treatment in patients with *DNAJC12* mutations.^{79,80} Pegvaliase converts Phe to trans-cinnamic acid and ammonia, and is highly effective at reducing blood Phe levels such that patients can return to an unrestricted diet. However, many *DNAJC12* patients may be within the normal range of Phe concentration (<360 $\mu\text{mol/L}$) and may be treated with neurotransmitter precursors alone or synthetic BH₄, L-DOPA, folinic acid and selegiline, and may remain on an unrestricted Phe diet which is preferable in early development. Nevertheless, HPA should be routinely monitored given the neurotoxicity of elevated Phe in blood and prospective evaluation is warranted. Untreated, *DNAJC12* mutations are a rare cause of infantile dystonia and young-onset parkinsonism that can be effectively managed with BH₄ or L-DOPA/5-HT replacement therapy.^{7,8,33,81} Adults with biallelic *DNAJC12* mutations may manifest with young-onset Parkinson's disease but not have HPA. Curiously, dystonia and parkinsonism co-exist in several neurological disorders, and they can be an alternate manifestation of the same underlying cause (*a forme fruste*) and an adverse response to therapy (drug-induced dyskinesia). For example, heterozygous mutations in *GCH1*, encoding GTPCH1, the rate-limiting enzyme in the synthesis of BH₄, may either manifest with postural dystonia in childhood which later generalizes, or as late-onset PD. Either syndrome may present, and even within different members of the same family.^{82,83} *GCH1* is also a genome-wide associated locus for sporadic, idiopathic late-onset PD. Although clearly related to catecholamine metabolism, the pathological mechanism for these alternate phenotypic presentations remains enigmatic.^{12,38,81}

Biochemically, *DNAJC12* is a co-chaperone for monoamine synthesis, yet its role in the intermediary metabolism of these neurotransmitters and hormones has yet to be elucidated.⁸ However, temporal and tissue-specific models of *DNAJC12* knock out may further our understanding of the pleiotropic functions of monoamines in the brain and periphery, and could reveal novel strategies to normalize

levels in pathological states. Conditional models could help decipher the ancient, integrated systems biology that monoamines modify, from times of acute and chronic stress, to excess in many psychiatric conditions (addiction, ADHD, autism and mood disorders), to deficits in neurologic and neurodegenerative disorders (dystonia, dementia and parkinsonism). For example, dopamine and other catecholamines, such as noradrenaline, modify PFC function, including attention, arousal and executive function.⁸⁴ Catecholamines such as dopamine may also have immunomodulatory effects as immune cells express dopamine receptors, although studies in the periphery are in their infancy.⁸⁵

Conclusion

This review highlights the role of *DNAJC12* variants in monoamine disorders and mild HPA; thus, validating its inclusion in newborn genetic screening. HPA is associated with neurotoxicity and neurodevelopmental disorders that can be alleviated by early diagnosis and treatment. Nevertheless, limited screening in the adult population means the full spectrum of clinical symptoms has yet to be fully appreciated. Dopamine deficiency is a prominent feature in patients with *DNAJC12* mutations that coincides with motor deficits such as dystonia and parkinsonism, and which is implicated in PFC dysfunction and impaired executive function.⁷⁻⁹ Serotonin is also drastically reduced in *DNAJC12* patients and relevant to mood disorders, including anxiety, apathy and depression, which are a common neuropsychiatric problems manifest in patients with idiopathic Lewy body disorders.⁸⁶ By documenting *DNAJC12* mutations in patients and related genotype-phenotype associations we highlight the potential for earlier diagnosis and intervention. Also, we highlight the utility of *in-vivo* models of *DNAJC12* to investigate the role of central and peripheral monoamines, their systems biology, and suggest knowledge of their integrated mechanisms of action is needed to inform the development of novel therapeutic strategies.

Figure legends

Fig 1. Monoamine biosynthesis. In a series of enzymatic reactions, GTP is converted into BH₄, which acts as a co-factor for enzymes involved in the synthesis of monoamines and nitric oxide. DNAJC12 protein interacts with PAH, TH, TPH1 and TPH2, supporting its role in monoamines synthesis. Mutations in *DNAJC12*, and enzymes involved in BH₄ synthesis and recycling, impair the synthesis of monoamines, resulting in overlapping neurological disorders.^{7,8,19,20} **Abbreviations:** GTPCH1: GTP cyclohydrolase 1; PTPS: 6-pyruvoyltetrahydropterin synthase; SPR: sepiapterin reductase; PCD: pterin-4a-carbinolamine dehydratase; DHPR: dihydropteridine reductase, eNOS: endothelial nitric oxide synthase; nNOS: neuronal nitric oxide synthase; iNOS: inducible nitric oxide synthase; PAH: phenylalanine hydroxylase; AADC: aromatic amino acid decarboxylase; TH: tyrosine hydroxylase; HVA: homovanillic acid; DH: dopamine β-hydrolase; PNMT: phenylethanolamine-N-methyl transferase; TPH1: tryptophan hydroxylase 1; TPH2: tryptophan hydroxylase 2; 5-HIAA: 5-hydroxyindoleacetic acid. This figure was created with Bio-render.com.

Fig 2. Genetic variants in *DNAJC12*. **A)** 3D image of DNAJC12 protein from AlphaFold. **B)** Variants in *DNAJC12* gene (top image), and the corresponding protein alteration (bottom image). Variants in *DNAJC12* gene and protein were identified in published articles, and within Clinvar, GnomAD and Uniprot databases. They were classified as pathogenic, likely pathogenic or likely benign according to the guidelines of the American College of Medical Genetics and Genomics, and Association of Molecular Pathology.³⁷ This figure was created with Bio-render.com.

Fig 3. Distribution of patients with *DNAJC12* mutations. Clinical data was extracted from 15 articles published between 2017 to 2023, with a total of 52 patients. Only the most common neurological features are depicted in this figure. **A)** Number of patients with neurological features by age group. **B)** Number of patients with, without or of unknown status for a specific neurological feature. **C)** Distribution of patients with *DNAJC12* mutations by age group. **D)** Origin of patients with *DNAJC12* mutations. Note

that “others” on the pie chart refers to the percentage of patients with undefined origin. **Abbreviations:**

ADHD: attention deficit hyperactivity disorder; GDD: global developmental delay.

Supplementary figure legends

Fig S1. Distribution of patients with parkinsonism and dystonia, and types and individual variants in *DNAJC12*. **A)** Number of patients with parkinsonism and dystonia per age group. **B)** The types of mutations in *DNAJC12*. Note that “others” on the pie chart refers to compound heterozygous variants with two different types of mutations. **C)** Variants in *DNAJC12* gene/protein. Only the most frequent variants are presented individually, and the remaining variants are shown under “others”.

Supplementary tables

Table S1. Detail clinical data of all the individuals identified with *DNAJC12* mutations. Clinical data was extracted from 15 articles published between 2017 to 2023, with a total of 52 patients. Their demographics, variants in *DNAJC12*, symptomology and treatment paradigms are detailed.

Author contributions

IBD contributed to conception and design of the review, acquisition and analysis of data, and drafted a significant portion of the manuscript or figures. MJF contributed to conception and design of the review, and drafted a significant portion of the manuscript or figures. JF and MB drafted a significant portion of the manuscript.

Potential conflicts of interest

Nothing to report.

References


1. Zarouchlioti C, Parfitt DA, Li W, et al. DNAJ Proteins in neurodegeneration: Essential and protective factors. *Philosophical Transactions of the Royal Society B: Biological Sciences* 2018;373:1–13.
2. Gorenberg EL, Chandra SS. The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease. *Front Neurosci* 2017;11:1–16.
3. Roosen DA, Blauwendraat C, Cookson MR, Lewis PA. DNAJC proteins and pathways to parkinsonism. *FEBS Journal* 2019;286(16):3080–3094.
4. Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. *Nat Rev Mol Cell Biol* 2018;19(6):365–381.
5. Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired Degradation of Mutant α -Synuclein by Chaperone-Mediated Autophagy. *Science* (1979) 2004;305(5688):1292–1295.
6. Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. *Science* (1979) 1996;273(5274):501.



7. Anikster Y, Haack TB, Vilboux T, et al. Biallelic Mutations in DNAJC12 Cause Hyperphenylalaninemia, Dystonia, and Intellectual Disability. *Am J Hum Genet* 2017;100(2):257–266.
8. Straniero L, Guella I, Cilia R, et al. DNAJC12 and dopa-responsive nonprogressive parkinsonism. *Ann Neurol* 2017;82(4):640–646.
9. van Spronsen FJ, Blau N, Harding C, et al. Phenylketonuria. *Nat Rev Dis Primers* 2021;7(1)
10. Blau N, Martinez A, Hoffmann GF, Thöny B. DNAJC12 deficiency: A new strategy in the diagnosis of hyperphenylalaninemias. *Mol Genet Metab* 2018;123(1):1–5.
11. Edvardson S, Cinnamon Y, Ta-Shma A, et al. A Deleterious Mutation in DNAJC6 Encoding the Neuronal-Specific Clathrin-Uncoating Co-Chaperone Auxilin, Is Associated with Juvenile Parkinsonism. *PLoS One* 2012;7(5):1–5.
12. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. *Nat Genet* 2014;46(9):989–993.
13. Nosková L, Stránecký V, Hartmannová H, et al. Mutations in DNAJC5, Encoding Cysteine-String Protein Alpha, Cause Autosomal-Dominant Adult-Onset Neuronal Ceroid Lipofuscinosis. *The American Journal of Human Genetics* 2011;89(2):241–252.
14. Vilariño-Güell C, Rajput A, Milnerwood AJ, et al. DNAJC13 mutations in Parkinson disease. *Hum Mol Genet* 2014;23(7):1794–1801.
15. Gaskill PJ, Khoshbouei H. Dopamine and norepinephrine are embracing their immune side and so should we. *Curr Opin Neurobiol* 2022;77:102626.
16. Martin AM, Young RL, Leong L, et al. The Diverse Metabolic Roles of Peripheral Serotonin. *Endocrinology* 2017;158(5):1049–1063.
17. Klein MO, Battagello DS, Cardoso AR, et al. Dopamine: Functions, Signaling, and Association with Neurological Diseases. *Cell Mol Neurobiol* 2019;39(1):31–59.
18. Kvetnansky R, Lu X, Ziegler MG. Chapter Seventeen - Stress-Triggered Changes in Peripheral Catecholaminergic Systems. In: Eiden LE, editor. *Advances in Pharmacology*. Academic Press; 2013 p. 359–397.
19. Fernstrom JD, Fernstrom MH. Tyrosine, Phenylalanine, and Catecholamine Synthesis and Function in the Brain ,2,. *J Nutr* 2007;137(6):1539S-1547S.
20. Brennenstuhl H, Jung-Klawitter S, Assmann B, Opladen T. Inherited Disorders of Neurotransmitters: Classification and Practical Approaches for Diagnosis and Treatment. *Neuropediatrics* 2019;50(1):2–14.
21. Werner ER, Blau N, Thöny B. Tetrahydrobiopterin: biochemistry and pathophysiology. *Biochemical Journal* 2011;438(3):397–414.
22. Opladen T, Hoffmann GF, Blau N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. *J Inherit Metab Dis* 2012;35(6):963–973.
23. Opladen T, Hoffmann G, Hörster F, et al. Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. *Movement Disorders* 2011;26(1):157–161.
24. Coughlin CR, Hyland K, Randall R, Ficicioglu C. Dihydropteridine Reductase Deficiency and Treatment with Tetrahydrobiopterin: A Case Report. In: Zschocke J, Gibson KM, Brown G, et al., editors. *JIMD Reports - Volume 10*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013 p. 53–56.
25. de Tommaso M, Arendt-Nielsen L, Defrin R, et al. Pain in Neurodegenerative Disease: Current Knowledge and Future Perspectives. *Behavioural Neurology* 2016;2016
26. Latremoliere A, Latini A, Andrews N, et al. Reduction of Neuropathic and Inflammatory Pain through Inhibition of the Tetrahydrobiopterin Pathway. *Neuron* 2015;86(6):1393–1406.
27. Tegeder I, Costigan M, Griffin RS, et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. *Nat Med* 2006;12(11):1269–1277.
28. McHugh PC. The tetrahydrobiopterin pathway: a novel target for the treatment of depression. *Pharmacogenomics* 2011;12(12):1625–1627.





29. Willemsen MA, Verbeek MM, Kamsteeg E-J, et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. *Brain* 2010;133(6):1810–1822.
30. Lee H-F, Tsai C-R, Chi C-S, et al. Aromatic l-amino acid decarboxylase deficiency in Taiwan. *European Journal of Paediatric Neurology* 2009;13(2):135–140.
31. Choi J, Djebbar S, Fournier A, Labrie C. The co-chaperone DNAJC12 binds to Hsc70 and is upregulated by endoplasmic reticulum stress. *Cell Stress Chaperones* 2014;19(3):439–446.
32. Jung-KC K, Himmelreich N, Prestegård KS, et al. Phenylalanine hydroxylase variants interact with the co-chaperone DNAJC12. *Hum Mutat* 2019;40(4):483–494.
33. Van Spronsen FJ, Himmelreich N, Rüfenacht V, et al. Heterogeneous clinical spectrum of DNAJC12-deficient hyperphenylalaninemia: From attention deficit to severe dystonia and intellectual disability. *J Med Genet* 2018;55(4):249–253.
34. Cartier EA, Parra LA, Baust TB, et al. A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. *Journal of Biological Chemistry* 2010;285(3):1957–1966.
35. Requena DF, Parra LA, Baust TB, et al. The molecular chaperone Hsc70 interacts with the vesicular monoamine transporter-2. *J Neurochem* 2009;110(2):581–594.
36. Parra LA, Baust TB, Smith AD, et al. The molecular chaperone Hsc70 interacts with tyrosine hydroxylase to regulate enzyme activity and synaptic vesicle localization. *Journal of Biological Chemistry* 2016;291(34):17510–17522.
37. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine* 2015;17(5):405–424.
38. Yoshino H, Nishioka K, Li Y, et al. GCH1 mutations in dopa-responsive dystonia and Parkinson's disease. *J Neurol* 2018;265:1860–1870.
39. Cobb SA, Wider C, Ross OA, et al. GCH1 in early-onset Parkinson's disease [Internet]. *Movement Disorders* 2009;24(14):2070–2075. Available from: <https://doi.org/10.1002/mds.22729>
40. Wider C, Melquist S, Hauf M, et al. Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1. [Internet]. *Neurology* 2008;70(16 Part 2):1377. Available from: http://n.neurology.org/content/70/16_Part_2/1377.abstract
41. Donnelly C, Ganesh J, Cork E, et al. eP011: Diagnosis of DNAJC12-deficient hyperphenylalaninemia offers targeted therapeutic options to counteract neurotransmitter deficiency. *Genetics in Medicine* 2022;24(3, Supplement):S6–S7.
42. Feng Y, Liu S, Tang C, et al. Identification of an inherited pathogenic DNAJC12 variant in a patient with hyperphenylalaninemia. *Clinica Chimica Acta* 2019;490:172–175.
43. Li M, Yang Q, Yi S, et al. Two novel mutations in DNAJC12 identified by whole-exome sequencing in a patient with mild hyperphenylalaninemia. *Mol Genet Genomic Med* 2020;8:1–6.
44. Veenma D, Cordeiro D, Sondheimer N, Mercimek-Andrews S. DNAJC12-associated developmental delay, movement disorder, and mild hyperphenylalaninemia identified by whole-exome sequencing re-analysis. *European Journal of Human Genetics* 2018;26(12):1867–1870.
45. de Sain-van der Velden MGM, Kuper WFE, Kuijper MA, et al. Beneficial effect of BH4 treatment in a 15-year-old boy with biallelic mutations in DNAJC12. In: *JIMD Reports*. Springer; 2018 p. 99–103.
46. Porta F, Neirotti A, Spada M. Restless legs syndrome in DNAJC12 deficiency. *Neurological Sciences* 2023;1–6.
47. Fan Y, Yang Z hua, Li F, et al. DNAJC12 mutation is rare in Chinese Han population with Parkinson's disease. *Neurobiol Aging* 2018;68:159.e1-159.e2.
48. Li C, Ou R, Chen Y, et al. Mutation Analysis of DNAJC Family for Early-Onset Parkinson's Disease in a Chinese Cohort. *Movement Disorders* 2020;35(11):2068–2076.
49. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol* 2019;18(12):1091–1102.




50. Çıkkı K, Yıldız Y, Yücel Yılmaz D, et al. DNACJ12 deficiency in patients with unexplained hyperphenylalaninemia: two new patients and a novel variant. *Metab Brain Dis* 2021;36(6):1405–1410.
51. Gallego D, Leal F, Gámez A, et al. Pathogenic variants of DNAJC12 and evaluation of the encoded cochaperone as a genetic modifier of hyperphenylalaninemia. *Hum Mutat* 2020;41(7):1329–1338.
52. Martín-Rivada Á, Palomino Pérez L, Ruiz-Sala P, et al. Diagnosis of inborn errors of metabolism within the expanded newborn screening in the Madrid region. *JIMD Rep* 2022;63(2):146–161.
53. van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. *Orphanet J Rare Dis* 2017;12(1):162.
54. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. *Lancet* 2010;376:1417–1427.
55. Gassió R, Artuch R, Vilaseca MA, et al. Cognitive functions in classic phenylketonuria and mild hyperphenyl-alaninaemia: experience in a paediatric population. *Dev Med Child Neurol* 2005;47(7):443–448.
56. Wong RSH, Mohammad S, Parayil Sankaran B, et al. Developmental delay and non-phenylketonuria (PKU) hyperphenylalaninemia in DNAJC12 deficiency: Case and approach [Internet]. *Brain Dev* 2023; Available from: <https://www.sciencedirect.com/science/article/pii/S0387760423000840>
57. Gunes D, Senturk L. A rare cause of hyperphenylalaninemia: four cases from a single family with DNAJC12 deficiency [Internet]. 2023; Available from: <https://doi.org/10.1515/jpem-2023-0049>
58. Christ SE, Moffitt AJ, Peck D, White DA. The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria. *Neuroimage Clin* 2013;3:539–547.
59. Wang L, Ma D, Sun Y, et al. Identification of two novel DNAJC12 gene variants in a patient with mild hyperphenylalaninemia. *Gene* 2023;869(147397):1–6.
60. Dyer CA. Pathophysiology of phenylketonuria. *Ment Retard Dev Disabil Res Rev* 1999;5(2):104–112.
61. Huttenlocher PR. The neuropathology of phenylketonuria: human and animal studies. *European Journal of Pediatrics*, suppl. Supplement 2000;159:S102-6.
62. Dyer CA, Kendler A, Philibotte T, et al. Evidence for Central Nervous System Glial Cell Plasticity in Phenylketonuria. *J Neuropathol Exp Neurol* 1996;55(7):795–814.
63. Thau-Zuchman O, Pallier PN, Savelkoul PJM, et al. High phenylalanine concentrations induce demyelination and microglial activation in mouse cerebellar organotypic slices. *Front Neurosci* 2022;16(926023):1–17.
64. Schoemans R, Aigrot M-S, Wu C, et al. Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites. *J Inherit Metab Dis* 2010;33(2):113–120.
65. Shefer S, Tint GS, Jean-Guillaume D, et al. Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse? *J Neurosci Res* 2000;61(5):549–563.
66. Mitchell JJ, Trakadis YJ, Scriver CR. Phenylalanine hydroxylase deficiency. *Genetics in Medicine* 2011;13(8):697–707.
67. Winn SR, Scherer T, Thöny B, Harding CO. High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU). *Mol Genet Metab* 2016;117(1):5–11.
68. Hikosaka O, Nakamura K, Sakai K, Nakahara H. Central mechanisms of motor skill learning [Internet]. *Curr Opin Neurobiol* 2002;12(2):217–222. Available from: <https://www.sciencedirect.com/science/article/pii/S0959438802003070>
69. Wise RA. Dopamine, learning and motivation [Internet]. *Nat Rev Neurosci* 2004;5(6):483–494. Available from: <https://doi.org/10.1038/nrn1406>
70. Wise RA. Roles for nigrostriatal—not just mesocorticolimbic—dopamine in reward and addiction [Internet]. *Trends Neurosci* 2009;32(10):517–524. Available from: <https://www.sciencedirect.com/science/article/pii/S0166223609001325>

71. Motiejunaite J, Amar L, Vidal-Petiot E. Adrenergic receptors and cardiovascular effects of catecholamines. *Ann Endocrinol (Paris)* 2021;82(3):193–197.
72. William Tank A, Lee Wong D. Peripheral and Central Effects of Circulating Catecholamines. In: *Comprehensive Physiology*. 2014 p. 1–15.
73. Kepser LJ, Homberg JR. The neurodevelopmental effects of serotonin: A behavioural perspective. *Behavioural Brain Research* 2015;277:3–13.
74. Daubert EA, Condron BG. Serotonin: A regulator of neuronal morphology and circuitry. *Trends Neurosci* 2010;33(9):424–434.
75. Chugani DC. Role of altered brain serotonin mechanisms in autism. *Mol Psychiatry* 2002;7:16–17.
76. Engel M, Smidt MP, van Hooft JA. The serotonin 5-HT₃ receptor: A novel neurodevelopmental target. *Front Cell Neurosci* 2013;7(76):1–8.
77. Guzel T, Mirowska-Guzel D. The Role of Serotonin Neurotransmission in Gastrointestinal Tract and Pharmacotherapy. *Molecules* 2022;27(1680):1–16.
78. O'Mahony SM, Clarke G, Borre YE, et al. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. *Behavioural Brain Research* 2015;277:32–48.
79. Longo N, Harding CO, Burton BK, et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. *The Lancet* 2014;384(9937):37–44.
80. Gupta S, Lau K, Harding CO, et al. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. *EBioMedicine* 2018;37:366–373.
81. Shetty AS, Bhatia KP, Lang AE. Dystonia and Parkinson's disease: What is the relationship? *Neurobiol Dis* 2019;132(104462):1–10.
82. Mencacci NE, Isaias IU, Reich MM, et al. Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. *Brain* 2014;137(9):2480–2492.
83. Guella I, Sherman HE, Appel-Cresswell S, et al. Parkinsonism in GTP cyclohydrolase 1 mutation carriers. *Brain* 2015;138(e349):1–2.
84. Arnsten AFT. Stress signalling pathways that impair prefrontal cortex structure and function. *Nat Rev Neurosci* 2009;10(6):410–422.
85. Channer B, Matt SM, Nickoloff-Bybel EA, et al. Dopamine, Immunity, and Disease. *Pharmacol Rev* 2023;75(1):62–158.
86. Ballard C, Aarsland D, Francis P, Corbett A. Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management. *Drugs Aging* 2013;30(8):603–611.









Articles	Patients	Demographics	Variants	Time course of disease and treatment
<p>Spronsen et al., 2017 Heterogeneous clinical spectrum of DNAJC12-deficient hyperphenylalaninemia: from attention deficit to severe dystonia and intellectual disability</p>	<p>Patient 1 (Described as Patient 1A in the study)</p>	<p>M, Dutch, non - consanguineous parents</p>	<p>DNA variation: Heterozygous c.85delC; 596G>T in exon 2 and 5 Protein alteration</p>	<p>5 days after birth: Diagnosed with HPA (Phe-500 $\mu\text{mol/L}$) via newborn screening (NBS). Development was normal in infancy. A Phe-restricted diet was implemented to regulate the plasma Phe concentration. 2.5 years: Diagnosed with attention deficit hyperactivity disorder (ADHD). 6 years: Neuropsychological assessment revealed poor executive function and ADHD. He was treated with BH₄, which allowed an unrestricted diet. 10 and 13 years: Neuropsychological assessment revealed normal executive function but minor problems with facial recognition, identification of facial emotions, thinking problems and social interaction. 13 years: Neuropsychological assessment revealed hypotonia with subtle signs of dystonia on the toes when walking. Cerebrospinal fluid (CSF) analysis revealed defects in dopamine and serotonin metabolites (5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA)). No reports after 13 years of age.</p>
	<p>Patient 2 (Described as 1B in the study)</p>	<p>F, Dutch, non - consanguineous parents</p>	<p>p. Gln29Lysfs*38; p.199Leuext*42</p>	<p>2 days after birth: Diagnosed with HPA (Phe-433 $\mu\text{mol/L}$) via NBS. Phe-restricted diet was initiated immediately. Early development was slow but within normal limits. 4 years: Noticed issues interacting with other kids at school. Neuropsychological assessment revealed signs of autism with no further investigation. She was treated with BH₄, which allowed an unrestricted diet. 8 and 11 years: Normal IQ and executive function with minor issues with facial recognition and identification of facial emotions. 11 years: Diagnosed with hypotonia. CSF analysis revealed defects in dopamine and serotonin metabolites (5-HIAA and HVA). No reports after 11 years of age.</p>
	<p>Patient 3 (Described as patient 2A in the study)</p>	<p>F, Saudi, consanguineous parents</p>	<p>DNA variation: Homozygous c.214C>T in exon 3 Protein alteration: p. Arg72*</p>	<p>14 days old: Diagnosed with HPA (Phe: 526 $\mu\text{mol/L}$) via NBS. Started treatment with BH₄ alongside L-Dopa/Carbidopa, 5-hydroxytryptophan (5-HTP) and folinic acid for a few months. Unfortunately, she was off medications due to non-compliance from her parents. 8 weeks: clinically evaluated and had normal growth parameters. 6 months and 12 months - patient assessment indicated relatively normal behaviour. No reports after 25 months of age.</p>
	<p>Patient 4 (Described as patient 2B in the study)</p>	<p>M, Saudi, consanguineous parents</p>		<p>Born with no NBS. 18 months old: Phe level was 509 $\mu\text{mol/L}$. He responded well to BH₄, but his parents refused BH₄ treatment and a Phe-restricted diet. 22 months: Phe level was 595 $\mu\text{mol/L}$. He showed signs of mild hypotonia but no abnormality in movement. No reports after 3 years of age.</p>
	<p>Patient 5 (Described as patient 3 in the study)</p>	<p>M, Saudi, consanguineous parents</p>		<p>3 weeks old: Diagnosed with HPA (blood Phe: 420 $\mu\text{mol/L}$). He was reported to have axial hypotonia, but no reports of the levels of monoamines, and other neurological status. 7 weeks: Started treatment with BH₄, L-Dopa, 5-HTP, and folinic acid (responded well on a moderate dose). No reports after 10 years of age.</p>
<p>Anikster et al., 2017 Biallelic Mutations in DNAJC12 Cause Hyperphenylalaninemia, Dystonia, and Intellectual Disability</p>	<p>Patient 6 (Described as A-IV-2 in the study)</p>	<p>M, Moroccan, consanguineous parents</p>	<p>DNA variation: Homozygous c.298-968_503-2603del (deletion of 6.943 kb), results in the</p>	<p>HPA was identified via NBS. He was born via Caesarean section at 36 weeks of gestation due to oligohydramnios. He appeared normal apart from axial hypotonia, which could be attributed to mild prematurity. He started BH₄ treatment. 10 months: Developed severe axial hypotonia with dystonia of the upper limbs and multidirectional nystagmus. CSF analysis revealed defects in dopamine and serotonin metabolites (5-HIAA and HVA). He was treated with L-DOPA/carbidopa, 5-HTP, folinic acid, and BH₄. The treatment resulted in the normalization of the neurological status within a few</p>

		deletion entire exon 4	weeks. 9.5 years: low normal IQ, verbal comprehension, perceptual reasoning, and processing speed. He didn't require special educational services. No extrapyramidal signs.
Patient 7 (Described as A-IV-4 in the study)	F, Moroccan, consanguineous parents		At birth: Diagnosed with HPA via NBS. 3 months: CSF analysis revealed defects in dopamine and serotonin metabolites. Clinical examination indicated normal neurological status. She Commenced treatment with L-DOPA/carbidopa, 5-HTP, folinic acid and BH ₄ . 22 months: Clinical examination remained normal. No reports after 22 months of age.
Patient 8 (Described as B-IV-1 in the study)	F, Arab Muslim descent, consanguineous parents	DNA variation: Homozygous c.158-2 A>T in intron 2	At birth: Diagnosed with HPA. Early development was normal. She was treated with Phe restricted diet. 2 years old: She had mild global developmental delay. 3.5 years: Developed lower left limb dystonia. 13 years: Clinical examination demonstrated obesity and cold cyanotic hands. Neurological examination revealed parkinsonism, which was exemplified by hypomimia. The cognitive assessment indicated moderate intellectual disability. CSF analysis revealed defects in dopamine and serotonin metabolites. Treated with L-Dopa/carbidopa and selegiline, which improved the Parkinsonia signs, but not the cognitive status. BH ₄ treatment improved both motor and neurocognitive statuses. No reports after 13 years of age.
Patient 9 (Described as B-IV-2 in the study)	M, Arab Muslim descent, consanguineous parents		NBS indicated normal Phe-levels. 10 years old: He was diagnosed with ADHD and fatigue. He experienced deterioration in school performance (noted as intellectual disability). Repeated testing revealed HPA. Clinical examination showed cold cyanotic hands and mild hypertonia of the lower limbs. CSF analysis revealed defects in dopamine and serotonin metabolites (5-HIAA and HVA). 10 years: Treated with L-Dopa/carbidopa and selegiline (side effects: dizziness). The treatment did not improve memory or school performance; thus, it was ceased. He was later treated with BH ₄ , which improved school performance, reduced fatigue, and increased exercise tolerance. No report after 10 years of age.
Patient 10 (Described as C-II-4 in the study)	M, Turkish, consanguineous parents	DNA variation: Homozygous c.215G>C in exon 3 Protein alteration: p. Arg72Pro	Born via Caesarean section. NBS revealed HPA. 6 months old: He had oculogyric crises, extrapyramidal signs, and dystonia. 2 years: Global developmental and speech delays. CSF analysis revealed defects in dopamine and serotonin metabolites (5-HIAA and HVA). 2.5 years: Treated with L-DOPA/Carbidopa, which improved neurological symptoms and development (e.g., oculogyric crises ceased). BH ₄ treatment was initiated due to a persistent increase in Phe levels. 7 years: Clinical assessment indicated minor deficits in gross motor function. No report after 7 years of age.
Patient 11 (Described as D-V-I in the study)	F, Moroccan, consanguineous parents	DNA variation: Homozygous c.298-968_503-2603del (deletion of 6.943 kb), results in the deletion of the entire exon 4.	No NBS performed at birth. 1 year old: She exhibited early autistic features and delayed motor development. 6 years: She had febrile seizures. She was diagnosed with HPA, and as a result, she initiated a Phe-restricted diet. 7-years: Initiation of BH ₄ treatment. 10 years: No improvement in autistic behaviour. She had muscle hypotonia, a broad-based gait, bradykinesia, dystonia, and intellectual disability. 10.5 years: CSF analysis revealed defects in dopamine and serotonin metabolites (5-HIAA and HVA). No report after 10.5 years of age.

Straniero et al., 2017 DNACJ12 and Dopa responsive nonprogressive Parkinsonism	Patient 12 (Described as Proband A in the study)	M, Canadian, non-consanguineous parents	DNA variation: Homozygous c.187A>T in exon 3 Protein alteration: p. Lys63*	13 years old: Juvenile parkinsonism which progressed to H & Y 3 by age 31 and remained stable. 32 years: Psychometric testing revealed mild intellectual disability. 56 and 73 years: PET indicated a mild non-progressive reduction of the presynaptic nigrostriatal imaging. Treatment with L-DOPA elicited a positive response (not specified when the treatment was commenced), but the patient experienced L-DOPA induced dyskinesia. 74 years: Patient died.
	Patient 13 (Described as Proband B in the study)	F, Italian, consanguineous parents	DNA variation: Homozygous c.79-2A>G in intron 1 Protein alteration	26 years old: She had anxiety and depression. 32 years: Diagnosed with tremulous Parkinsonism. She benefited significantly from L-DOPA treatment but developed L-DOPA induced dyskinesia. 52 years: DaT SPECT indicated a lower limit of normality in the right putamen. 55 years: neuropsychological assessment indicated a mild cognitive impairment (including mild global impairment, mild frontal lobe, and visuospatial dysfunction), borderline intellectual disability, sleep disorder and fatigue. 57 years: Second DaT SPECT was normal. No report after 59 years of age. Additional follow-up by Porta et al., 2023 indicated that the patient had restless leg syndrome (RLS), especially at bedtime, which resulted in insomnia, and relieved by movement. ⁴⁶ Regular blood tests ruled out iron, vitamins, and nerve conduction deficiencies.
	Patient 14 (Described as Proband B in the study)	M, Italian, consanguineous parents	p. Val27Trpfs*14	51 years of old: Diagnosed with tremulous parkinsonism and prominent psychotic symptoms (hallucination and delusion). Benefited significantly from L-DOPA treatment but developed L-DOPA induced dyskinesia. 55 years: Neuropsychological assessment revealed mild cognitive impairment (mild global impairment, frontal lobe, and visuospatial dysfunction), sleep disorder and fatigue. No report after 58 years of age.
Ciki et al., 2021 DNACJ12 deficiency in patients with unexplained hyperphenylalaninemia: two new patients and a novel variant	Patient 15 (Described as Case 1 in the study)	M, Turkish, non-consanguineous parents	DNA variation: Homozygous c.404del in exon 4 Protein alteration: p. Arg135Lysfs*21	NBS revealed HPA (Phe:318 µmol/L). 26 days old: Parents refused BH ₄ treatment. Phe-restricted diet was initiated. CSF analysis revealed defects in dopamine and serotonin metabolites (5-HIAA and HVA). 6 years: Normal developmental growth. He was neurological asymptomatic. No report after 6 years of age.
	Patient 16 (Described as Case 2 in the study)	F, Turkish, non-consanguineous parents	DNA variation: Homozygous c.158-2 A>T in intron 2.	23 days old: NBS indicated HPA (Phe: 410 µmol/L). Physical examination was normal. She was treated with sapropterin dihydrochloride. 3 months: She had axial hypotonia and developmental delays (e.g., delays in gross motor skills). 9, 13 and 18 months: Personal, social, language and fine motor skills were normal. 22 months: Diagnosed with developmental delays. CSF analysis revealed defects in dopamine and serotonin metabolites (5-HIAA and HVA). 41 months: Received special education. Initiation of treatment with L-DOPA/ benserazide and 5-HT, and continuation of sapropterin dihydrochloride. No reports after 41 months of age
	Patients 17 and 18 (Parents for Patients 15 and 16)	M, Turkish F, Turkish	DNA variation: Homozygous c.404del in exon 4. Protein alteration: p. Arg135Lysfs*21	Segregation analysis revealed that the patient's parents were also homozygous for the <i>DNAJC12</i> c.404del variant. However, they were asymptomatic but refused to perform neuro-psychometric (these individuals have bi-allelic mutations in <i>DNAJC12</i> , and as a result, they are included in the total number of <i>DNAJC12</i> patients).

<p>Veenma et al., 2018 DNAJC12-associated developmental delay, movement disorder, and mild hyperphenylalaninemia identified by whole-exome sequencing re-analysis</p>	<p>Patient 19 (Described as Patient 1 in the study)</p>	<p>M, Afghan, consanguineous parents</p>	<p>DNA variation: Homozygous c.58_59delGG in exon 1 Protein alteration: p. Gly20Metfs*2</p>	<p>13 days after old: NBS revealed HPA (Phe: 271 $\mu\text{mol/L}$). 6 months: Revealed signs of global developmental delays. 2 years: Diagnosed with an autism spectrum disorder. 6 years: He was treated with sapropterin dihydrochloride. No reports after 6 years of age.</p>
	<p>Patient 20 (Described as Patient 2 in the study)</p>	<p>M, Afghan, consanguineous parents</p>		<p>He was born via C-section. NBS was normal. He had early infantile onset developmental delay. 4 years old: Diagnosed with ADHD. 8 years: Diagnosed with an autism spectrum disorder. 11.5 years: Plasma amino acid analysis revealed HPA (Phe: 538 $\mu\text{mol/L}$). In addition, CSF analysis revealed defects in dopamine and serotonin metabolites (5-HIAA and HVA). 15 years: Prescribed oral sapropterin dihydrochloride. His parents reported a subjective improvement in his behaviour. 17 years: cognitive impairment, dystonia in his hand and feet, and hyperkinetic movement. No reports after 17 years of age.</p>
<p>Li et al., 2020 Two novel mutations in DNAJC12 identified by whole-exome sequencing in a patient with mild hyperphenylalaninemia</p>	<p>Patient 21</p>	<p>M, Chinese</p>	<p>DNA variation: Heterozygous c.182delA; c.306C>G in exons 3 and 4 Protein alteration: Lys61Argfs*6; p. His102Gln</p>	<p>At birth: Born at normal conditions. NBS revealed HPA (Phe: 223.14 $\mu\text{mol/L}$). The patient was placed on a Phe-restricted diet once he was diagnosed. 1 year: The patient received a combined treatment of L-DOPA, 5-HTP and BH₄. 2 years: It was reported that the patient had impaired adaptability, gross motor, fine motor, language and social-emotional behaviour (age at onset was not specified), which were alleviated by combined treatment with L-DOPA, 5-HTP and BH₄. No reports after 2 years of age.</p>
<p>Feng et al., 2019 Identification of an inherited pathogenic DNAJC12 variant in a patient with hyperphenylalaninemia</p>	<p>Patient 22</p>	<p>M, Chinese, non-consanguineous parents</p>	<p>DNA variation: Homozygous c.262del in exon 3 Protein alteration: p. Gln88Ser*6</p>	<p>Born with normal birth weight. NBS revealed HPA (Phe:185 $\mu\text{mol/L}$). 8 months old: He could not roll over in either direction or sits by himself. 11 months: He could not crawl and stand without help. 13 months: Diagnosed with global developmental delay. He started treatment with oral sapropterin dihydrochloride, L-DOPA/benserazide, and 5-HTP. 14 months: Phe-restricted diet was added to the previous treatments. 18 months: It was reported that the patient had impaired adaptability, language, gross motor, fine motor, and social-emotional behaviour (age at onset was not specified), all of which were improved by oral sapropterin dihydrochloride, L-DOPA/benserazide, 5-HTP and Phe-restricted diet. No report after 18 months of age.</p>
<p>Gallego et al., 2020 Pathogenic variants of DNAJC12 and evaluation of the encoded cochaperone as a genetic modifier of hyperphenylalaninemia</p>	<p>Patient 23 (Described as Patient 1 in the study)</p>	<p>Spanish</p>	<p>DNA variation: Heterozygous c.298-2A>C; c.524G>A in intron 3 and exon 5 Protein alteration: p.?, p. Trp175*</p>	<p>23 days old: Diagnosed with HPA via NBS (Phe: 158 $\mu\text{mol/L}$). Reported as neurologically asymptomatic, and no treatment (including dietary restrictions). No reports after 6 years, 6 months of age.</p>
	<p>Patient 24 (Described as Patient 2 in the study)</p>		<p>DNA variation: Homozygous c.524G>A in exon 5 Protein alteration:</p>	<p>1 month, 17 days old: Diagnosed with HPA via NBS (Phe: 120 $\mu\text{mol/L}$). Reported as neurologically asymptomatic, and no treatment (including dietary restrictions). Exception: the patient had migraines. No reports after 9 years, 4 months of age.</p>

			p. Trp175*	
	Patient 25 (Described as Patient 3 in the study)		DNA variation: Homozygous c.524G>A in exon 5 Protein alteration: p. Trp175*	1 months, 13 days old: Diagnosed with HPA via NBS (Phe:139 µmol/L). Reported as neurologically asymptomatic, and no treatment (including dietary restrictions). No reports after 7 years, 10 months of age.
	Patient 26 (Described as Patient 4 in the study)		DNA variation: Homozygous c.524G>A in exon 5 Protein alteration: p. Trp175*	6 months, 15 days old: Diagnosed with HPA via NBS (Phe:127 µmol/l). Reported as neurologically asymptomatic, and no treatment (including dietary restrictions). No reports after 13 years, 3 months of age.
	Patient 27 (Described as Patient 5 in the study)		DNA variation: Homozygous c.524G>A in exon 5 Protein alteration: p. Trp175*	27 days old: Diagnosed with HPA via NBS (Phe: 224 µmol/l). Reported as neurologically asymptomatic, and no treatment (including dietary restrictions). No reports after 6 years, 10 months.
	Patient 28 (Described as Patient 6 in the study)		DNA variation: Heterozygous c.502+1G>C; c.524G>A in intron 4 and exon 5 Protein alteration: p. ?; p. Trp175*	21 months old: Diagnosed with HPA via NBS (Phe: 442 µmol/l). Initiation of Phe-restricted diet and L-DOPA. Diagnosed with speech delay, oculogyric crisis, West's syndrome and myoclonic epilepsy. No reports after 6 years, 6 months of age.
	Patient 29 (Described as Patient 7 in the study)		DNA variation: Homozygous c.524G>A in exon 5 Protein alteration: p. Trp175*	Diagnosis with HPA via NBS (Phe:131 µmol/l). Reported as neurologically asymptomatic. Treated with sapropterin dihydrochloride from 14 months to 6 years. Reported to have febrile episodes, and hypopigmented spots on the trunk. No reports after 8 years, 9 months of age.
	Patient 30 (Described as Patient 8 in the study)		DNA variation: Heterozygous c.297+5G>T; c.524G>A in intron 4 and exon 5	No additional information

			Protein alteration: p.? p. Trp175*	
	Patient 31 (Described as Patient 9 in the study)		DNA variation: Homozygous c.524G>A in exon 5 Protein alteration: p. Trp175*	Diagnosis with HPA via NBS (Phe:184 µmol/l). Reported as neurologically asymptomatic. No treatment (including dietary restrictions). No reports after 30 years, 4 months of age.
	Patient 32 (Described as Patient 10 in the study)		DNA variation: Heterozygous. c.309G>T; c.524G>A in exon 4 and 5. Protein alteration: p. Trp103Cys; p. Trp175*	9 Years old: Diagnosed with HPA (Phe:266µmol/l). Diagnosed with ADHD, speech delay, intellectual disability, anxiety, dystonia, behavioural problems, aggressivity and limb hypertonia. No treatment (including dietary restrictions). No reports after 16 years, 3 months of age.
	Patient 33 (Described as Patient 11 in the study)		DNA variation: Homozygous c.524G>A in exon 5 Protein alteration: p. Trp175*	12 months old: Diagnosed with HPA (Phe: 218 µmol/l). Reported as neurologically asymptomatic. No treatment (including dietary restrictions). No reports after 14 years of age.
	Patient 34 (Described as Patient 12 in the study)		DNA variation: Homozygous c.524G>A in exon 5 Protein alteration: p. Trp175*	38 days old: diagnosed with HPA (Phe level: 240 µmol/l). Reported as neurologically asymptomatic. No treatment (including dietary restrictions). No reports after 10 years, 4 months of age.
	Patient 35 (Described as Patient 13 in the study)		DNA variation: Heterozygous c.502+1G>C; c.524G>A Protein alteration: p.? p. Trp175*	23 days old: Diagnosed with HPA (324 µmol/l). Reported as neurologically asymptomatic. Treated with sapropterin dihydrochloride from 3–8 years old. No reports after 8 years, 2 months of age.
	Patient 36 (Described as Patient 14 in the study)		DNA variation: Homozygous c.524G>A in exon 5 Protein alteration:	34 years old: Diagnosed with HPA (Phe: 236 µmol/l). Reported as neurologically asymptomatic. No treatment (including dietary restrictions) No reports after 40 years of age.

			p. Trp175*	
	Patient 37 (Described as Patient 15 in the study)		DNA variation: Homozygous c.524G>A in exon 5 Protein alteration: p. Trp175*	1 month, 4 days old: Diagnosed with HPA (122 - 421 µmol/l). Reported as neurologically asymptomatic. No treatment (including dietary restrictions). No reports after 5 years of age.
	Patient 38 (Described as Patient 16 in the study)		DNA alteration c.309G>T; c.524G>A in exon 4 and 5 Protein alteration p. Trp175*; p. Trp103Cys	2 months old: Diagnosed with HPA (Phe:204 µmol/l), and with ADHD, speech delay, intellectual disability, and macrocephaly. No treatment (including dietary restrictions) No reports after 7 years, 4 months of age.
	Patient 39 (Described as Patient 17 in the study)		DNA variation: Homozygous c.524G>A in exon 5 Protein alteration: p. Trp175*	7 days old: Phe level: 97 µmol/l. Diagnosed with ADHD, autism, and intellectual disability. No treatment (including dietary restrictions). No reports after 7 years, 3 months of age.
	Patient 40 (Described as Patient 18 in the study)		Homozygous c.524G>A p. Trp175* Concomitant heterozygous mutation in PAH c.194T>C p. Ile65Thr	1 month, 10 days old: diagnosed with HPA (Phe: < 373 µmol/l). Excluded from the analysis of patients with <i>DNAJC12</i> mutations due to a mutation in PAH.
	Patient 41 (Described as Patient 19 in the study)		Homozygous c.524G>A (p. Trp175*) with a Concomitant heterozygous mutation in PAH, c.143T>C p. Leu48Ser	6 days old: Diagnosed with HPA (Phe: 151µmol/l). Excluded from the analysis of patients with <i>DNAJC12</i> mutations due to a mutation in PAH.
	Patient 42 (Described as Patient 20 in the study)		Homozygous (p. Trp175Ter) c.524G>A. Also has PAH (p.?) c.912+1G>A	1 month, 29 days old: Diagnosed with HPA (Phe: 163 µmol/l). Excluded from the analysis of patients with <i>DNAJC12</i> mutations due to a mutation in PAH.

	Patient 43 (Described as Patient 21 in the study)		(p. Trp175Ter) c.524G>A (second allele ?). Also has PAH (p.?) c.441+5G>T	Diagnosed with HPA (level >151 μmol/l) (max. 236 μmol/l). Excluded from the analysis of patients with DNAJC12 mutations due to a mutation in PAH.
Velden et al., 2018 Beneficial Effect of BH4 Treatment in a 15-Year-Old Boy with Biallelic Mutations in DNAJC12	Patient 44	M, Moroccan, consanguineous parents	DNA variation: Homozygous c.298-968_503-2603del (deletion of 6.943 kb), results in the deletion of the entire exon 4.	0 -1 year old: Reports indicated normal behaviour. 7 years: Diagnosed with developmental delay, social withdrawal, extrapyramidal movement disorder, dysarthria, impaired gait, dystonia, and fatigue. Metabolic examination revealed HPA (Phe: 564 μmol/L). CSF analysis revealed defects in dopamine and serotonin metabolites (5-HIAA and HVA). He initiated treatment sapropterin dihydrochloride, L-DOPA, carbidopa and 5-HTP, which improved clinical symptoms such that the patient became more energetic with improvements in the movement disorders. 15 years: Diagnosed with DNAJC12 deficiency (no further assessment).
Donnelly et al., 2022 Diagnosis of DNAJC12-deficient hyperphenylalaninemia offers targeted therapeutic options to counteract neurotransmitter deficiency	Patient 45	F	DNA variation: Homozygous c.235C>T in exon 3 Protein alteration: p. Arg79*	Born prematurely via C-section at 25 weeks gestation and discovered to have HPA via NBS. 16 months old: Diagnosed with Hypotonia, developmental delay and speech delay. The fine motor was normal. CSF analysis revealed defects in dopamine and serotonin metabolites (5-HIAA and HVA). She started treatment with sapropterin dihydrochloride, L-DOPA, and 5-HTP, which improved cognition and motor function (no further assessment).
Rivada et al., 2021 Diagnosis of inborn errors of metabolism within the expanded newborn screening in the Madrid region	Patient 46	Spanish	DNA variation: Homozygous c.524G>A in exon 5 Protein alteration: p. Trp175*	Diagnosed with HPA via NBS - the median Phe level for the study: 162.4 μmol/l [123.1–265.0]
	Patient 47		DNA variation: Homozygous c.524G>A in exon 5 Protein alteration: p. Trp175*	
	Patient 48		DNA variation: Heterozygous c.502 + 1G > C; c.524G > A in intron 4 and exon 5	

			Protein alteration: p.?.; p. Trp175*	
	Patient 49		DNA variation: Heterozygous c.298-2A > C; c.524G > A in intron 3 and exon 5 Protein alteration: p.?.; p. Trp175*,	
Wang et al., 2023 Identification of two novel <i>DNAJC12</i> gene variants in a patient with mild hyperphenylalaninemia	Patient 50	F, Chinese, non-consanguineous parents	DNA variation: 158-1G>A; c.336delG in intron 2 and exon 4 Protein alteration: Val53Aspfs*15; Met112Ilefs*44	She was born at 38 weeks gestation after an uneventful pregnancy. 3 days postnatal: She had HPA (Phe: 258 μmol/L). 2 months: A repeat measurement of Phe levels confirmed the diagnosis of HPA (Phe:169 μmol/L). No treatment (including dietary restrictions). She was reported to be neurologically asymptomatic from 2 months of age until 7 months, to which there was no additional assessment.
Porta et al., 2023 Restless legs syndrome in <i>DNAJC12</i> deficiency	Patient 51	?,Italian	DNA variation: Homozygous c.79-2A>G; c.595 T>C intron 1 and exon 5 Protein alteration p. Val27Trpfs*14; p.?	22 years of old: Received at a new department with 3 years of clinical history of idiopathic hyperprolactinemia and galactorrhea. Clinical examination revealed movement disorders, including dyskinesias of the upper extremities and gait disturbances with mild diurnal fluctuation. Treated with L-DOPA, 5-HTP, selegiline, and entacapone, which improved the clinical symptoms significantly. At subsequent follow-up, the patient reported painful sensation in the lower limbs, mainly occurring at night and relieved with movement. The levels of iron and vitamins were normal. Additional treatment with pramipexole eradicated the RLS symptoms and further improved the movement disorders and prolactin secretion profile.
Wong et al.2023 Developmental delay and non-phenylketonuria (PKU) hyperphenylalaninemia in <i>DNAJC12</i> deficiency: Case and approach	Patient 52	M, non-consanguineous parents, Sudanese	DNA variation: Homozygous: c.78 + 1del	At birth: Diagnosed with HPA (247 mmol/L) via NBS and placed immediately on a low Phe-restricted diet. 2 years: severe developmental delay. 3-years: diagnosed with autism spectrum disorder. Motor development was preserved. 5 years: CSF analysis revealed defects in dopamine and serotonin metabolites (HVA and 5-HIAA). Exome sequencing identified c.78 + 1del variant in <i>DNAJC12</i> . 6 years: Started treatment with serotonin precursor (5-hydroxytryptophan). 7 years: Treated with Sapropterin dihydrochloride no observable clinical benefits (has global developmental delay, severe autism, aggression, and hyperactivity).

<p>Gunes & Senturk A rare cause of hyperphenylalaninemia: four cases from a single family with DNAJC12 deficiency</p>	<p>Patient 53 (Described as Patient A1 in the study)</p>	<p>F, consanguineous parents, Syria</p>	<p>DNA variation: Homozygous: c.158-2A>T in intron 2.</p>	<p>16 days after birth: Diagnosed with HPA via NBS. Physical examination was normal. She was identified to have ventricular septal defect and patent foramen ovale (no other neurological deficits were reported). CSF analysis revealed defects in dopamine and serotonin metabolites (HVA and 5-HIAA). Treated with Sapropterin dihydrochloride, L-DOPA/carbidopa and 5-HTP.</p>
	<p>Patient 54 (described as Patient A2 in the study)</p>	<p>F, consanguineous parents, Syria</p>	<p>DNA variation: Homozygous: c.158-2A>T in intron 2.</p>	<p>7-year-old: Diagnosed with HPA. Her physical examination was unremarkable with the exception of obesity. Treated with Sapropterin dihydrochloride, L-DOPA/carbidopa and 5-HTP.</p>
	<p>Patient 55 (described as Patient B1 in the study)</p>	<p>M, Consanguineous, Syria</p>	<p>DNA variation: Homozygous: c.158-2A>T in intron 2.</p>	<p>13-day old: Identified with HPA via NBS. 26-month: Diagnosed with growth retardation, and postpartum respiratory distress. 6-months: Treated with sapropterin dihydrochloride. He had normal physical examination (no other neurological deficits were reported).</p>
	<p>Patient 56 (described as Patient B2 in the study)</p>	<p>F, Consanguineous, Syria</p>	<p>DNA variation: Homozygous: c.158-2A>T in intron 2.</p>	<p>9-year-old: Diagnosed with HPA upon screening. Normal neuromotor development, difficulty with learning and language (no other neurological deficits were reported). Treated with sapropterin dihydrochloride, L-DOPA/carbidopa and 5-HTP.</p>